Kusumoto Y, Nakata K, Muro T, Furukawa R, Kono K, Ishii N, Munehisa T, Koji T, Nagataki S, Kaneda H
Oncodev Biol Med. 1983;4(6):C95-100.
14 patients with hepatocellular carcinoma and one with a hepatoblastoma were given AFP antibodies and changes in serum AFP levels and clinical courses were observed. Anti-human AFP horse IgG was purified by immunoadsorbent column chromatography. 1 mg of the purified antibody was able to bind 100-150 micrograms of AFP. 200-800 mg were given to each patient, according to their AFP levels. Also, conventional anti-cancer agents were administered consecutively. In all cases, the serum AFP levels measured by RIA decreased rapidly to undetectable levels within 24-48 h after the infusion. Then, in seven of 15 cases, the relatively low level was maintained for periods of 10-96 weeks. In the remaining eight cases, the serum AFP level increased again after 1-2 weeks and rose further with clinical deterioration. Since the antibody administered was undetectable in the serum within 2 weeks after its infusion, it is suggested that the AFP antibody had an inhibitory effect on the production or the release of AFP in some patients.
对14例肝细胞癌患者和1例肝母细胞瘤患者给予甲胎蛋白（AFP）抗体，并观察血清AFP水平的变化和临床病程。通过免疫吸附柱层析法纯化抗人AFP马IgG。1毫克纯化抗体能够结合100 - 150微克AFP。根据患者的AFP水平，给每位患者注射200 - 800毫克。同时，连续给予传统抗癌药物。在所有病例中，通过放射免疫分析（RIA）测量的血清AFP水平在输注后24 - 48小时内迅速降至检测不到的水平。然后，在15例中的7例中，相对较低的水平维持了10 - 96周。在其余8例中，血清AFP水平在1 - 2周后再次升高，并随着临床病情恶化进一步上升。由于输注后2周内血清中检测不到所给予的抗体，提示AFP抗体对某些患者的AFP产生或释放有抑制作用。
